Literature DB >> 8441277

Adjuvant chemotherapy for osteogenic sarcoma of the extremity with sequential adriamycin and cisplatin.

A B Pathak1, S H Advani, R S Iyer, S K Pai, R Gopal, K S Nadkarni, T K Saikia, P A Kurkure, C N Nair, V R Pai.   

Abstract

Twenty-nine patients with high-grade nonmetastatic osteogenic sarcoma of the extremities were treated with adjuvant chemotherapy following definitive surgery. Chemotherapy consisted of systemic intravenous Adriamycin and cisplatin in a sequential fashion given for six courses. Nineteen out of 29 patients are alive and continuously disease free over a follow-up period ranging from 9+ to 30+ months. The relapse-free survival was 72%, and overall survival for the entire group was 69%. Median survival is not reached yet. Six out of 29 patients relapsed, of which 1 patient is alive for 6+ months after relapse. Three patients died of chemotherapy toxicity. The results were superior to historical controls treated with surgery alone. The need for more aggressive treatment approaches is discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8441277     DOI: 10.1002/jso.2930520313

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  1 in total

Review 1.  Indian data on bone and soft tissue sarcomas: A summary of published study results.

Authors:  Anant Ramaswamy; Bharat Rekhi; Sameer Bakhshi; Sachin Hingmire; Manish Agarwal
Journal:  South Asian J Cancer       Date:  2016 Jul-Sep
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.